Business context and reporting period
Invivyd, Inc. is a clinical-stage biopharmaceutical company developing monoclonal antibodies for prevention and treatment of viral diseases, led by COVID-19 candidates. This is its annual report for the fiscal year ended December 31, 2022; the filing does not provide a separate Q4 income statement or cash-flow breakdown.
The company had no approved products and generated no revenue in 2022 or 2021. Its lead candidate, VYD222, is an engineered version of adintrevimab. In March 2023, Invivyd said it would prioritize VYD222 rather than the NVD200 combination, and planned a Phase 1 trial in Q1 2023, followed—if data were positive—by pivotal Phase 3 trials. These are plans, not reported results.
Financial performance and liquidity
| Metric | 2022 | 2021 | Change / context |
|---|---|---|---|
| Revenue | $0 | $0 | No product or other revenue reported. |
| Research and development expense | $179.2 million | $182.9 million | Down $3.7 million, about 2%; lower adintrevimab trial costs were partly offset by personnel and NVD200 spending. |
| Selling, general and administrative expense | $47.0 million | $36.5 million | Up $10.5 million, about 29%, including higher public-company and professional-service costs. |
| Total operating expenses | $248.0 million | $226.9 million | Up $21.1 million, about 9%, including $17.4 million of warrant expense in 2022. |
| Net loss | $241.3 million | $226.8 million | Loss increased $14.5 million, about 6%. |
| Net loss per share | $2.23 | $5.32 | Weighted-average shares rose to 108.3 million from 42.6 million, largely reflecting the 2021 IPO and preferred-stock conversion. |
| Cash used in operating activities | $220.0 million | $184.7 million | Operating cash use increased about 19%. |
| Cash, cash equivalents and marketable securities | $372.0 million | $591.4 million | Down $219.4 million. 2022 year-end consisted of $92.1 million cash and equivalents and $279.9 million marketable securities. |
Gross margins and operating margins are not meaningful because the company had no revenue. Management estimated that year-end 2022 cash, cash equivalents and marketable securities would fund operations and capital expenditures into the second half of 2024, based on assumptions that could prove incorrect. The filing reports no debt borrowings. Lease liabilities totaled $3.7 million at year-end; current liabilities were $25.0 million against current assets of $376.9 million.
Net cash used in investing was $230.7 million, primarily reflecting purchases of marketable securities, partly offset by maturities. Net cash from financing was $0.5 million, versus $662.7 million in 2021, when the company completed its IPO and issued preferred stock. Accordingly, the fall in cash balances alone does not represent operating cash burn; operating cash use was $220.0 million.
Material changes, outlook and risks
- Program reprioritization: Adintrevimab lost neutralizing activity against Omicron BA.2; the company paused and later closed its Phase 2/3 trials and paused an EUA submission. It shifted toward VYD222, while repurposing remaining contracted manufacturing batches for the new candidate.
- Development outlook: VYD222 showed in-vitro neutralizing activity against variants including XBB.1.5, but clinical performance and regulatory acceptance are unproven. The company is seeking alignment with regulators on a potentially expedited pathway, including use of neutralizing-antibody titers as a surrogate marker; no agreement or authorization is assured.
- Funding and operations: Invivyd expects continuing losses and will need additional capital to meet its objectives. It relies on third parties for trials and manufacturing, particularly WuXi Biologics, its sole CDMO to date, and faces supply-chain, capacity and China-related risks.
- Commitments and unusual items: A remaining $18.1 million manufacturing commitment was expected to be incurred and paid in 2023; in March 2023 the batches were repurposed for VYD222. WuXi provided a low-eight-figure credit against services, most of which reduced 2022 expenses and liabilities. The $17.4 million PHP warrant expense was non-cash: warrants for up to 6.8 million shares were issued to Population Health Partners for services, with vesting tied to market-capitalization targets or specified change-of-control events. PHP also received $0.5 million monthly under a six-month work order; two Invivyd directors are PHP partners.
- Legal and regulatory matters: A securities class action filed in January 2023 alleges misleading statements about adintrevimab’s activity against Omicron. The SEC requested documents in March 2023 concerning related testing, statements and communications. The company intends to defend the lawsuit and cooperate with the SEC; outcomes and potential costs are uncertain.
- Other risks: Future variants could undermine candidate activity; EUA availability and duration are uncertain; competition includes vaccines and antivirals; and regulatory, reimbursement, clinical, manufacturing and financing outcomes remain uncertain. The company reported a prior material weakness in financial controls as remediated in 2021 and concluded its controls were effective at December 31, 2022.
Important facts for investors to verify
- Whether VYD222’s planned clinical milestones occurred, and whether clinical data support safety, efficacy and a viable regulatory pathway.
- Whether neutralizing activity persists against currently circulating variants and whether regulators accept the proposed surrogate-endpoint strategy.
- Actual cash burn, any financing plans, and whether the estimated runway into the second half of 2024 remains achievable.
- Manufacturing readiness, the use and remaining balance of the WuXi credit, the $18.1 million commitment, and the implications of reliance on a single CDMO.
- Developments in the securities lawsuit and SEC inquiry, including any financial exposure or operational impact.